Gan, Hui K.
van den Bent, Martin
Lassman, Andrew B.
Reardon, David A.
Scott, Andrew M.
Article History
First Online: 4 July 2017
Competing interests
: H.K.G. is conducting an investigator-initiated study with AbbVie; has received travel support and research funding from AbbVie and Ignyta; honoraria from AbbVie, BMS, Merck Serono and Pfizer; and is affiliated with the Ludwig Institute for Cancer Research (New York, New York, USA). M.vD.B. has received honoraria from AbbVie, Actelion, Blue Earth Diagnostics, BMS, Cavion, Celldex, Merck, Novocure and Roche; and research funding from AbbVie and Roche. A.B.L. has received honoraria from Bioclinica, Cortice Biosciences, Genentech, Oxigene, prIME Oncology, Sapience Therapeutics and VBI Vaccines. D.A.R. has received honoraria from and has a consulting or advisory role with AbbVie, Amgen, BMS, Cavion, Celldex, Genentech, Inovio, Juno Pharmaceuticals, Merck, Novartis, Novocure, Oxigene, Regeneron, Roche and Stemline Therapeutics; is involved in speakers' bureaus with Merck and Roche; and has received research funding from Celldex, Incyte and Midatech. A.M.S. owns stock in and has an advisory role with Life Science Pharmaceuticals; received research funding from AbbVie, Avipep and Daiichi Sankyo; has patents, royalties, or other intellectual property with Abbvie, Kalobios, Life Science Pharmaceuticals, and Ludwig Institute for Cancer Research.